American Cancer Society Cancer Action Network INC

FY2025 Defense self-filed

Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP.

FY2025 Indian/Native American Affairs self-filed

Issues relating to Indian Health Services and the Congressional Native American Caucus. FY26 appropriations for the Indian Health Service. ACS CAN advocates for full funding for FY26 and advanced FY27 appropriations to ensure American Indians and Alaska Natives have access to quality and affordable health care services. FY26 appropriations for the Initiative for Improving Native American Cancer Outcomes under the NIMHD and NCI. ACS CAN advocates for the continuation of full funding for the program to support research, education, outreach, and clinical access related to cancer in Native American populations.

FY2025 Health Issues self-filed

Access to Care One Big Beautiful Bill, H.R. 1. Advocate to protect Medicaid from cuts as part of the FY25 budget reconciliation process. Advocate for the inclusion of the enhanced premium tax credits as part of the package. Health Care Affordability Act, H.R.247, S.46. House and Senate bills would permanently extend the enhanced Affordable Care Act tax credits. Association Health Plans Act, H.R.2528. This bill would amend the Employee Retirement Income Security Act of 1974 to treat association health plans as employers. Self-Insurance Protection Act, H.R. 2571. This bill would amend the Employee Retirement Income Security Act of 1974 to exclude from the definition of health insurance coverage certain medical stop-loss insurance. Access to Breast Cancer Diagnosis Act, H.R. 3037/S.1500. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Women and Lung Cancer Research and Preventative Services Act of 2025, H.R.2319, S.1157. This bill requires the Department of Health and Human Services working with the Department of Defense, to conduct an interagency review to evaluate the status of and identify opportunities for research on women and lunch cancer preventative services. Health Disparities Nancy Gardner Sewell Medicare Early Detection Screening Coverage Act, H.R. 842, S. 339. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer Act, H.R. 2381/S.1866. Reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through 2030 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.1406. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Equality Act, H.R. 15/S. 1503. This bill prohibits discrimination based on sex, sexual orientation, or gender identity with respect to businesses, employment, housing, federally funded programs, and other settings. Henrietta Lacks Congressional Gold Medal Act, H.R. 3498/ S.1893. Legislation to award posthumously a Congressional Gold Medal to Henrietta Lacks, in recognition of her immortal cells which have made invaluable contributions to global health, scientific research, our quality of life, and patients' rights. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022 (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Accelerating Kids Access to Care Act, S.752, H.R.1509. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Give Kids and Chance Act of 2025, S.932, H.R. 1262. Legislation that would accelerate pediatric cancer treatments and expand access to live-saving therapies for children battling rare diseases, spur drug development for pediatric rare diseases, improve outcomes for patients, and close gaps in pediatric drug research. One Big Beautiful Bill, H.R. 1. Advocate to protect Medicaid for children with cancer from cuts as part of the FY25 budget reconciliation process. Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA). Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to include funding for palliative care research in the FY26 LHHS Appropriations bill. Federal Health Care Programs Increased Funding Levels for Cancer Research and Prevention. Ensure continued progress in the fight against cancer at the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Advanced Research Projects Agency for Health (ARPA-H), and the Centers for Disease Control and Preventions (CDC), Division of Cancer Prevention and Control (DCPC). Women and Lung Cancer Research and Preventive Services Act of 2025, H.R.2319, S.1157 This bill requires the Department of Health and Human Services, working with the Department of Defense, to conduct an inter- agency review to evaluate the status of and identify opportunities for research on women and lung cancer preventive services. Department of Defense Cancer Research Funding. Ensure continued funding for cancer research within the DOD's Congressionally Directed Medical Research Program. Clinical Trials Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. To amend the Internal Revenue Act of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

H.R. 1 H.R. 247 S. 46 H.R. 2528 H.R. 2571 H.R. 3037 S. 1500 H.R. 2319 S. 1157 H.R. 842 S. 339 H.R. 2381 S. 1866 H.R. 1300 S. 297 H.R. 1406 H.R. 15 S. 1503 H.R. 3498 S. 1893 S. 752 H.R. 1509 S. 932 H.R. 1262 H.R. 3521 H.R. 4184

FY2025 Taxation/Internal Revenue Code self-filed

One Big Beautiful Bill Act, H.R. 1. Advocate to protect Medicaid from cuts as part of the FY25 budget reconciliation process. Advocate for the inclusion of the enhanced premium tax credits as part of the package. Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Health Care Affordability Act, H.R. 247, S. 46. House and Senate bills would permanently extend the enhanced Affordable Care Act tax credits.

H.R. 1 H.R. 3521 H.R. 4184 H.R. 247 S. 46

FY2025 Tobacco self-filed

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments.; Issues relating to FDA regulation of flavors, electronic cigarettes and cigars

FY2025 Budget/Appropriations self-filed

One Big Beautiful Bill Act, H.R. 1. Advocate to protect Medicaid from cuts as part of the FY25 budget reconciliation process. Advocate for inclusion of the enhanced premium tax credits as part of the package. FY25 and FY26 House Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP and funding for the Initiative for Improving Native American Cancer Outcomes through NCIs coordination with NIMHD. FY25 and FY26 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. FY25 VA Appropriations for PACT Act Funding. ACS CAN advocates for full funding for the PACT Act. FY25 AND FY26 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY25 and FY26 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of flavors, electronic cigarettes, and cigars.

H.R. 1

FY2025 Medicare/Medicaid self-filed

One Big Beautiful Bill Act, H.R. 1. Advocate to protect Medicaid from cuts as part of the FY25 budget reconciliation process. Advocate for inclusion of the enhanced premium tax credits as part of the package. Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, H.R. 842, S.339. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Lung Cancer Screening and Prevention Act, H.R. 140. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Accelerating Kids Access to Care Act, S.752, H.R. 150. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received.

H.R. 1 H.R. 842 S. 339 H.R. 140 S. 752 H.R. 150

FY2025 Medical/Disease Research/Clinical Labs self-filed

Clinical Trial Modernization Act, H.R. 3521. Increase diversity in access to clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

H.R. 3521 H.R. 4184

FY2025 Defense self-filed

Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP.

FY2025 Indian/Native American Affairs self-filed

Issues relating to Indian Health Services and the Congressional Native American Caucus

FY2025 Health Issues as client

Palliative Care and Hospice Education and Training Act.

FY2025 Health Issues self-filed

Access to Care One Big Beautiful Bill, P.L. 119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Health Care Affordability Act, H.R.247, S.46. Bill would permanently extend the enhanced Affordable Care Act tax credits. Association Health Plans Act, H.R.2528, S.1847. This bill would amend the Employee Retirement Income Security Act of 1974 to treat association health plans as employers. Self-Insurance Protection Act, H.R. 2571. This bill would amend the Employee Retirement Income Security Act of 1974 to exclude from the definition of health insurance coverage certain medical stop-loss insurance. Access to Breast Cancer Diagnosis Act, H.R. 3037/S.1500. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Women and Lung Cancer Research and Preventative Services Act of 2025, H.R.2319, S.1157. This bill requires the Department of Health and Human Services working with the Department of Defense, to conduct an interagency review to evaluate the status of and identify opportunities for research on women and lunch cancer preventative services. Education and Awareness Requires Learning (EARLY) Act, H.R. 4541, S. 2339. This bill would reauthorize the CDC program that supports young and high-risk women as well as their providers to better understand breast health. Safe Step Act, H.R. 5509, S. 2903. Bill would require an exceptions process for any medication step therapy protocol in commercial insurance plans. Bipartisan Premium Tax Credit Extension Act, H.R. 5145, Bill would extend the enhanced ACA tax credits for one year. Breaking the Gridlock Act, H.R. 1834. Bill would extend the enhanced Affordable Care Act tax credits for three years. Common Ground for Affordable Health Care Act, H.R.6575. Bill would extend the enhanced Affordable Care Act tax credits for one year and make other adjustments. Bipartisan Health Insurance Affordability Act, H.R.6501. Bill would extend the enhanced Affordable Care Act tax credits for two years and make other adjustments. Medically Tailored Home-Delivered Meals Demonstration Pilot Act, H.R.5439, S.2834. The bill would create a pilot program in Medicare for beneficiaries with diet-related diseases to receive medically tailored meals to their own home. Health Disparities Nancy Gardner Sewell Medicare Early Detection Screening Coverage Act, H.R. 842, S. 339. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer Act, H.R. 2381, S.1866. Reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through 2030 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.1406. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Equality Act, H.R. 15, S. 1503. This bill prohibits discrimination based on sex, sexual orientation, or gender identity with respect to businesses, employment, housing, federally funded programs, and other settings. Henrietta Lacks Congressional Gold Medal Act, H.R. 3498, S.1893. Legislation to award posthumously a Congressional Gold Medal to Henrietta Lacks, in recognition of her immortal cells which have made invaluable contributions to global health, scientific research, our quality of life, and patients' rights. Prevent HPV Cancer Act of 2025, H.R. 6561. This bill would create a national public awareness campaign to promote education and awareness of HPV and HPV-associated cancers and would increase funding for the NBCCED program to boost breast and cervical cancer screening. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Accelerating Kids Access to Care Act, S.752, H.R.1509. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Give Kids and Chance Act of 2025, S.932, S. 3302, H.R. 1262. Legislation that would accelerate pediatric cancer treatments and expand access to live-saving therapies for children battling rare diseases, spur drug development for pediatric rare diseases, improve outcomes for patients, and close gaps in pediatric drug research. One Big Beautiful Bill, P.L. 119-21, Advocate to protect pediatric cancer patients in implementation of changes to Medicaid under the law. Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA), S. 22870, H.R. 4425. Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to include funding for palliative care research in the FY26 LHHS Appropriations bill. Federal Health Care Programs Department of Defense Cancer Research Funding. Ensure continued funding for cancer research within the DOD's Congressionally Directed Medical Research Program. Clinical Trials Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. To amend the Internal Revenue Act of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

H.R. 247 S. 46 H.R. 2528 S. 1847 H.R. 2571 H.R. 3037 S. 1500 H.R. 2319 S. 1157 H.R. 4541 S. 2339 H.R. 5509 S. 2903 H.R. 5145 H.R. 1834 H.R. 6575 H.R. 6501 H.R. 5439 S. 2834 H.R. 842 S. 339 H.R. 2381 S. 1866 H.R. 1300 S. 297 H.R. 1406 H.R. 15 S. 1503 H.R. 3498 S. 1893 H.R. 6561 S. 752 H.R. 1509 S. 932 S. 3302 H.R. 1262 S. 22870 H.R. 4425 H.R. 3521 H.R. 4184

FY2025 Taxation/Internal Revenue Code self-filed

One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Health Care Affordability Act, H.R. 247, S. 46. Bill would permanently extend the enhanced Affordable Care Act tax credits. Bipartisan Premium Tax Credit Extension Act, H.R. 5145. Bill would extend the enhanced ACA tax credits for one year. Breaking the Gridlock Act, H.R. 1834. Bill would extend the enhanced Affordable Care Act tax credits for three years. CommonGround for Affordable Health Care Act, H.R.6575. Bill would extend the enhanced Affordable Care Act tax credits for one year and make other adjustments. Bipartisan Health Insurance Affordability Act, H.R.6501. Bill would extend the enhanced Affordable Care Act tax credits for two years and make other adjustments. A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium credits, S.2824. Bill would extend the enhanced ACA tax credits for two years.

H.R. 3521 H.R. 4184 H.R. 247 S. 46 H.R. 5145 H.R. 1834 H.R. 6575 H.R. 6501 S. 2824

FY2025 Tobacco self-filed

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments.; Issues relating to FDA regulation of flavors, electronic cigarettes and cigars. Strengthening Task Force Operations to Prevent Illicit Vaping Act (STOP Illicit Vaping Act), H.R.6845, / S.3569, Bill would codify and strengthen the federal multi-agency task force, led by the Department of Justice and Food and Drug Administration, to coordinate enforcement, information sharing, and strategy to combat the illegal importation, distribution, and sale of unauthorized e-cigarettes. Increasing Access to Lung Cancer Screening Act, H.R.6178. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance.

H.R. 6845 S. 3569 H.R. 6178

FY2025 Budget/Appropriations self-filed

One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. FY25 Labor, Health, and Human Services CR provisions. ACS CAN advocated for full implementation of the law and for funding to be issued consistent with statute. FY26 House and Senate Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP and funding for the Initiative for Improving Native American Cancer Outcomes through NCIs coordination with NIMHD. FY26 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. ACS CAN advocates for increases in programs that advance research for cancers include the Peer Reviewed Cancer Research Program (PRCRP). FY26 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY26 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of flavors, electronic cigarettes, and cigars. Indian Programs Advance Appropriations Act of 2025, S. 2771, H.R. 5328. The bill would provide advance appropriations authority for certain accounts of the Bureau of Indian Affairs and Bureau of Indian Education of the Department of the Interior and the Indian Health Service.

S. 2771 H.R. 5328

FY2025 Medicare/Medicaid self-filed

One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, H.R. 842, S.339. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Lung Cancer Screening and Prevention Act, H.R. 140. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Accelerating Kids Access to Care Act, S.752, H.R. 150. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Ensuring Access to Essential Providers Act, S.2793. Bill would require Medicare Advantage plans to cover items and services furnished by certain essential community providers. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Access to Genetic Counselor Services Act, H.R.6280. Bill would expand coverage of genetic counseling services under Medicare. Lung Cancer Screening and Prevention Act of 2025, H.R. 1406. This bill authorizes Medicare coverage of additional types of lung cancer screening tests that are approved by the FDA, regardless of whether they are recommended by the United States Preventive Services Task Force (USPSTF). Increasing Access to Lung Cancer Screening Act, H.R.6178. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance.

H.R. 842 S. 339 H.R. 140 S. 752 H.R. 150 S. 2793 H.R. 5269 S. 2761 H.R. 6280 H.R. 1406 H.R. 6178

FY2025 Medical/Disease Research/Clinical Labs self-filed

Clinical Trial Modernization Act, H.R. 3521. Increase diversity in access to clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services.

H.R. 3521 H.R. 4184 H.R. 5269 S. 2761

FY2025 Defense self-filed

Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP.

FY2025 Indian/Native American Affairs self-filed

Issues relating to Indian Health Services and the Congressional Native American Caucus. FY26 appropriations for the Indian Health Service. ACS CAN advocates for full funding for FY26 and advanced FY27 appropriations to ensure American Indians and Alaska Natives have access to quality and affordable health care services. Indian Programs Advance Appropriations Act of 2025, S. 2771, H.R. 5328. The bill would provide advance appropriations authority for certain accounts of the Bureau of Indian Affairs and Bureau of Indian Education of the Department of the Interior and the Indian Health Service. FY26 appropriations for the Initiative for Improving Native American Cancer Outcomes under the NIMHD and NCI. ACS CAN advocates for the continuation of full funding for the program to support research, education, outreach, and clinical access related to cancer in Native American populations.

S. 2771 H.R. 5328

FY2025 Health Issues as client

Palliative Care and Hospice Education and Training Act.

FY2025 Budget/Appropriations as client

Health and Human Services appropriations for cancer research and prevention

FY2025 Budget/Appropriations as client

Health and Human Services appropriations for cancer research and prevention.

FY2025 Health Issues as client

Palliative Care and Hospice Education and Training Act.

FY2025 Health Issues self-filed

Access to Care FY25 Budget Resolution. Advocate to protect Medicaid from cuts as part of the FY25 Budget resolution and reconciliation process. Advocate for the inclusion of the enhanced premium tax credits as part of the package. Inflation Reduction Act (IRA). ACS CAN actively monitors implementation of the Inflation Reduction Acts Medicare Drug Price negotiation provisions to ensure cancer patients have access to costly prescription drugs. ACS CAN also supports the Medicare Prescription Payment Plan, which allows Part D enrollees to spread their out-of-pocket costs over the plan year. Health Care Affordability Act, H.R.247, S.46. House and Senate bills would permanently extend the enhanced Affordable Care Act tax credits. Help CoPays Act S.864; Help Ensure Lower Patient Copays Act. These bills would require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Safe Step Act. This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2025, S.1261. This bill extends coverage of telehealth services under Medicare. Telehealth Modernization Act. Modifies requirements relating to coverage of telehealth services under Medicare and permanently extends telehealth flexibilities first authorized during the public health emergency. Association Health Plans Act, H.R.2528. This bill would amend the Employee Retirement Income Security Act of 1974 to treat association health plans as employers. Telehealth Benefit Expansion for Workers Act. This bill would allow employers to offer standalone telehealth benefits to all employees. Self-Insurance Protection Act, H.R. 2571. This bill would amend the Employee Retirement Income Security Act of 1974 to exclude from the definition of health insurance coverage certain medical stop-loss insurance. Preserving Telehealth, Hospital, and Ambulance Access Act. This bill allows employers to offer stand-alone telehealth benefits to all employees. This includes employees who are eligible for enrollment in their employer's group health plan. Alan Reinstein Ban Asbestos Now Act of 2025. This bill prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. Access to Breast Cancer Diagnosis Act. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Women and Lung Cancer Research and Preventative Services Act of 2025, H.R.2319, S.1157. This bill requires the Department of Health and Human Services working with the Department of Defense, to conduct an interagency review to evaluate the status of and identify opportunities for research on women and lunch cancer preventative services. Health Disparities Nancy Gardner Sewell Medicare Early Detection Screening Coverage Act, H.R. 842, S. 339. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer) Act, H.R. 2381. Reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through 2030 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.1406. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022 (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Accelerating Kids Access to Care Act, S.752, H.R.1509. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Give Kids and Chance Act of 2025, S.932, H.R. 1262. Legislation that would accelerate pediatric cancer treatments and expand access to live-saving therapies for children battling rare diseases, spur drug development for pediatric rare diseases, improve outcomes for patients, and close gaps in pediatric drug research. Preserve Medicaid Coverage for Children and Families. Advocate to protect Medicaid for children with cancer. For these families Medicaid plays an especially critical role as a safety net. In many states, a child is eligible for Medicaid and CHIP coverage upon receiving a childhood cancer diagnosis, providing necessary and timely access to quality, uninterrupted care. Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA). Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to include funding for palliative care research in the FY26 LHHS Appropriations bill. Patient Navigation for People with Cancer. Legislation and policies to increase access to patient navigation for people with cancer, prioritizing policies that create sustainable funding to ensure access to patient navigation services across the cancer continuum. Patient Navigation Assistance Act. This bill would require state Medicaid programs to provide patient navigation services for enrollees. Federal Health Care Programs Increased Funding Levels for Cancer Research and Prevention. Ensure continued progress in the fight against cancer at the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Advanced Research Projects Agency for Health (ARPA-H), and the Centers for Disease Control and Preventions (CDC) cancer programs, including the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Women and Lung Cancer Research and Preventive Services Act of 2025, H.R.2319, S.1157 This bill requires the Department of Health and Human Services, working with the Department of Defense, to conduct an inter- agency review to evaluate the status of and identify opportunities for research on women and lung cancer preventive services. Department of Defense Cancer Research Funding. DOD's Congressionally Directed Medical Research Program. Cancer Alan Reinstein Ban Asbestos Act. This bill prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. Clinical Trials Clinical Trial Modernization Act. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. Harley Jacobsen Clinical Trial Participant Income Exemption Act. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

H.R. 247 S. 46 S. 864 S. 1261 H.R. 2528 H.R. 2571 H.R. 2319 S. 1157 H.R. 842 S. 339 H.R. 2381 H.R. 1300 S. 297 H.R. 1406 S. 752 H.R. 1509 S. 932 H.R. 1262

FY2025 Taxation/Internal Revenue Code self-filed

Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 8412. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Health Care Affordability Act, H.R. 247, S. 46. House and Senate bills would permanently extend the enhanced Affordable Care Act tax credits.

H.R. 8412 H.R. 7090 H.R. 7418 H.R. 247 S. 46

FY2025 Tobacco self-filed

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments.; Issues relating to FDA regulation of flavors, electronic cigarettes and cigars

FY2025 Budget/Appropriations self-filed

FY25 Budget Resolution. Actively advocate to protect Medicaid from cuts as part of the FY25 Budget resolution and reconciliation process. Advocate for inclusion of the enhanced premium tax credits as part of the package. FY25 and FY26 House Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP and funding for the Initiative for Improving Native American Cancer Outcomes through NCIs coordination with NIMHD. FY25 and FY26 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. FY25 VA Appropriations for PACT Act Funding. ACS CAN advocates for full funding for the PACT Act. FY25 AND FY26 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY25 and FY26 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of flavors, electronic cigarettes, and cigars.

FY2025 Medicare/Medicaid self-filed

Bridge To Medicaid Act: Bill would extend enhanced ACA premium tax credits to low-income Medicaid enrollees in the coverage gap. Inflation Reduction Act (IRA). ACS CAN actively monitors implementation of the Inflation Reduction Acts Medicare Drug Price negotiation provisions to ensure cancer patients have access to costly prescription drugs. ACS CAN also supports the Medicare Prescription Payment Plan, which allows Part D enrollees to spread their out-of-pocket costs over the plan year. Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2025, S.1261. This bill extends coverage of telehealth services under Medicare. Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, H.R. 842, S.339. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Lung Cancer Screening and Prevention Act, H.R. 140. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Equitable Community Access to Pharmacist Services Act H.R.1770, S.2477. This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, vaccines, and treatment for COVID-19, influenza, and certain other illnesses. Accelerating Kids Access to Care Act, S.752, H.R. 150. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received.

S. 1261 H.R. 842 S. 339 H.R. 140 H.R. 1770 S. 2477 S. 752 H.R. 150

FY2025 Medical/Disease Research/Clinical Labs self-filed

Clinical Trial Modernization Act. Increase diversity in access to clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. Harley Jacobsen Clinical Trial Participant Income Exemption Act. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Alan Reinstein Ban Asbestos Act. This bill prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos.

FY2025 Defense self-filed

Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP.

FY2025 Indian/Native American Affairs self-filed

Issues relating to Indian Health Services and the Congressional Native American Caucus

FY2025 Health Issues as client

Palliative Care and Hospice Education and Training Act.

FY2024 Indian/Native American Affairs self-filed

Issues relating to Indian Health Services and the Congressional Native American Caucus.

FY2024 Health Issues self-filed

Access to Care Inflation Reduction Act (IRA). ACS CAN actively monitors implementation of the Inflation Reduction Acts Medicare Drug Price negotiation provisions to ensure cancer patients have access to costly prescription drugs. ACS CAN also supports the Medicare Prescription Payment Plan, which allows Part D enrollees to spread their out-of-pocket costs over the plan year. Enhanced Advanced Premium Tax Credits, H.R. 9774, Improving Health Insurance Affordability Act of 2023, S.5194. House and Senate bills would permanently extend the enhanced Affordable Care Act tax credits. Help CoPays Act S.1375; Help Ensure Lower Patient Copays Act, H.R.830. This bill requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Safe Step Act, S.652, H.R. 2630. This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a group health plan or a health insurance issuer. Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2023 H.R.4189, S.2016. This bill expands coverage of telehealth services under Medicare. Telehealth Modernization Act of 2924, H.R. 7623. Modifies requirements relating to coverage of telehealth services under Medicare. Permanently expands telehealth flexibilities first authorized during the public health emergency. The Preserving Telehealth, Hospital, and Ambulance Access Act, H.R. 8261. This bill allows employers to offer stand-alone telehealth benefits to all employees. This includes employees who are eligible for enrollment in their employer's group health plan. Drug Shortage Prevention Act, H.R. 3008. This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand for certain critical essential medicines that may result in a shortage. Protecting Americans from Unsafe Drugs Act of 2023, H.R. 2500. This bill expands the authority of the Secretary of the Department of Health and Human Services (HHS) to order the recall of controlled substances to cover all drugs. Ensuring Access to Lifesaving Drugs Act of 2023, H.R. 3793. This bill allows the Food and Drug Administration (FDA) to obtain additional information from manufacturers of life-saving drugs in order to assess and potentially modify the drug's expiration date. (The bill defines life-saving drug as a medical countermeasure or a drug that is in short supply and that is life-supporting, life-sustaining, or intended to be used to prevent or treat a debilitating disease or condition in humans or animals.) Specifically, the FDA may order a manufacturer of a life-saving drug to submit data and other information from any stage of the drug's development in order to assess the drug's stability and the longest supported expiration date. If such information is not readily available, the FDA may order the manufacturer to conduct additional studies. The FDA may require changes to the drug's label accordingly. Manufacturers that fail to comply are subject to civil penalties. Medical Device Shortage Reduction Act of 2023, H.R. 3807. This bill expands the scope of required notifications about medical device shortages beyond public health emergencies. Protecting PAHPA Action of 2023, H.R. 4697. ACS CAN is lobbying on all provisions related to drug shortages. This bill extends through FY2028 and modifies various programs and activities that support public health preparedness and response. The bill also addresses matters concerning shortages of drugs and medical devices and recalls of drugs. Essential Medicines Strategic Stockpile Act of 2023, H.R. 405. This bill requires the Department of Health and Human Services (HHS) to create a pilot program to test the effectiveness of acquiring, maintaining, managing, and distributing a stockpile of generic drugs at risk of shortage. Alan Reinstein Ban Asbestos Now Act of 2023, H.R. 2402, S. 1069. This bill prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. RAPID Reserve Act, S. 2510. This bill improves supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies. Rolling Active Pharmaceutical Ingredient and Drug Reserve Act, H.R.6802. A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies Drug Shortage Prevention and Mitigation Act, S.2586. This legislation would address the ongoing drug shortage crisis. Access to Breast Cancer Diagnosis Act of 2023, H.R.3851, S.2464. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Health Disparities Nancy Gardner Sewell Multi-Cancer Early Detection Act, H.R. 2407. This bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, S.2085. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer) Act, S.1840, H.R.3916. Reauthorization of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2024 through 2028 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, S.2821, H.R.1826. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.6693. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Health Equity and Accountability Act (HEAA), H.R. 9161, S. 4773. Legislation to eliminate racial and ethnic health disparities. We actively advocate for provisions (HEAA), which focuses on health inequalities, societal injustices, and their intersection with immigration status, age, disability, sex, gender, sexual orientation, and socioeconomic status. Increased Funding for the National Institute for Minority Health and Health Disparities. Reducing disparities in the use of recommended preventive services targeting three leading causes of death in the United States - cancer, heart disease, and diabetes. Cancer Drug Parity Act of 2023, S.2039, H.R.6301. Level the playing field for cancer patients by ensuring that the cost-sharing for oral anticancer drugs is on par with intravenous chemotherapy, thereby removing a significant financial obstacle to effective treatment. Henrietta Lacks Enhancing Cancer Research Act of 2019 Report. Request for Congress to urge the Government Accountability Office (GAO) to revisit the Henrietta Lacks Enhancing Cancer Research Act of 2019 report, with respect to promoting diverse participation in cancer clinical trials and addressing fully the request for insight into either implementation challenges for current federal activities or recommendations for additional activities and policy changes related to clinical trial diversity. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022 (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Gabriella Miller Kids First Research Act 2.0, H.R. 623, S. 1523. This bill reauthorizes through FY2028 a pediatric disease research initiative within the National Institutes of Health (NIH) and requires the NIH to coordinate pediatric research activities to avoid duplicative efforts. Additionally, the Department of Health and Human Services must report to Congress about research funded through the initiative. Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers (PREVENT) Act, H.R.3633. Legislation that would help prevent cancer and save lives by raising awareness about HPV and HPV-related cancers through a national campaign to educate providers, parents, and the public about the life-saving HPV vaccine. It would also boost resources for a federal initiative to provide access to timely cervical cancer screening and diagnostic services for uninsured and underserved individuals. Accelerating Kids Access to Care Act, S.2372, H.R.4758. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Creating Hope Reauthorization Act of 2024, H.R. 7384. This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.) Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA), S.2243. Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to ensure the U.S. Congress appropriates specific money for palliative care research, upon enactment of the FY2024 LHHS Appropriations bill. Patient Navigation for People with Cancer. Legislation and policies to increase access to patient navigation for people with cancer, prioritizing policies that create sustainable funding to ensure access to patient navigation services across the cancer continuum. Patient Navigation Assistance Act, H.R. 9446. This bill would require state Medicaid programs to provide patient navigation services for enrollees. Cancer Survivorship Comprehensive Cancer Survivorship Act (CCSA), S.2213, H.R.4363. ACS CAN supports legislation that sets new standards for survivorship from diagnosis to end of life, ensuring the best and most seamless experience for survivors, and their families and caregivers throughout the journey. CCSA will address gaps in survivorship care and develop needed standards to improve the overall patient-centered quality of care and navigation needs that cancer survivors and their families experience. Federal Health Care Programs Increased Funding Levels for Cancer Research and Prevention. Ensure continued progress in the fight against cancer at the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Advanced Research Projects Agency for Health (ARPA-H), and the Centers for Disease Control and Preventions (CDC) cancer programs. CDC Cancer Programs, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Regulatory issues related to healthy food and dietary guidelines PC CARE Act, H.R.1315. This bill establishes a committee to develop, implement, and periodically revise a plan to coordinate federal activities and programs concerning prostate cancer, including those related to research, screening, diagnosis, and treatment. Women and Lung Cancer Research and Preventive Services Act of 2023, H.R.4534, S.2245. This bill requires the Department of Health and Human Services to conduct an interagency review of the status of women and lung cancer. Department of Defense Appropriations Act, 2024 H.R.4365, S.2587. DOD Congressionally Directed Medical Research Program. Cancer Alan Reinstein Ban Asbestos Act, H.R.2402, S.1069. This bill generally prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. The President may, on application, grant exemptions from the prohibition in situations where it is necessary to protect national security interests. Nutrition Medical Nutrition Act H.R.6407, S.3297. A bill to amend title XVIII of the Social Security Act to expand the availability of medical nutrition therapy services under the Medicare program Farm, Food, and National Security Act of 2024, H.R.8467. To provide for the reform and continuation of agricultural and other programs of the Department of Agriculture through fiscal year 2029, and for other purposes. Rural Prosperity and Food Security Act, S.5335. To provide for the reform and continuation of agricultural and other programs of the Department of Agriculture through fiscal year 2029, and for other purposes. Clinical Trials Clinical Trial Modernization Act, H.R. 8412. Increase diversity in clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. NIH Clinical Trial Diversity Act, S.1701, H.R.3503. Legislation to increase the diversity of participants in all National Institutes of Health (NIH)-funded trials. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

H.R. 9774 S. 5194 S. 1375 H.R. 830 S. 652 H.R. 2630 H.R. 4189 S. 2016 H.R. 7623 H.R. 8261 H.R. 3008 H.R. 2500 H.R. 3793 H.R. 3807 H.R. 4697 H.R. 405 H.R. 2402 S. 1069 S. 2510 H.R. 6802 S. 2586 H.R. 3851 S. 2464 H.R. 2407 S. 2085 S. 1840 H.R. 3916 S. 2821 H.R. 1826 H.R. 6693 H.R. 9161 S. 4773 S. 2039 H.R. 6301 H.R. 623 S. 1523 H.R. 3633 S. 2372 H.R. 4758 H.R. 7384 S. 2243 H.R. 9446 S. 2213 H.R. 4363 H.R. 1315 H.R. 4534 S. 2245 H.R. 4365 S. 2587 H.R. 6407 S. 3297 H.R. 8467 S. 5335 H.R. 8412 S. 1701 H.R. 3503 H.R. 7090 H.R. 7418

FY2024 Taxation/Internal Revenue Code self-filed

Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 8412. Increase diversity in clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Enhanced Advanced Premium Tax Credits H.R. 9774, Improving Health Insurance Affordability Act of 2023, S.5174. Bills to expand the eligibility of taxpayers for the refundable tax credit for coverage under a qualified health plan and increase cost-sharing subsidies under the Affordable Care Act

H.R. 8412 H.R. 7090 H.R. 7418 H.R. 9774 S. 5174

FY2024 Tobacco self-filed

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments; Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars; Increasing Access to Lung Cancer Screening Act, H.R. 4286. This bill provides for coverage without prior authorization requirements of annual lung cancer screenings under Medicaid, Medicare, and private health insurance for individuals for whom screenings are recommended under U.S. Preventive Services Task Force guidelines. It also expands Medicaid coverage of counseling and pharmacotherapy for cessation of tobacco use to all individuals, rather than only pregnant women.

H.R. 4286

FY2024 Budget/Appropriations self-filed

Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars; FY25 House Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. FY25 VA Appropriations for PACT Act Funding. ACS CAN advocates for full funding for the PACT Act. FY25 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY25 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of menthol, flavors, electronic cigarettes, and cigars.

FY2024 Medicare/Medicaid self-filed

Bridge To Medicaid Act: extends enhanced premium tax credits to low-income Medicaid enrollees in the coverage gap. Medicaid Unwinding. ACS CAN is working to ensure that states comply with federal law by actively monitoring their data submissions and tracking the impact on Medicaid beneficiaries. We will continue to urge the Centers for Medicare & Medicaid Services (CMS) to take corrective action if states fail to comply with federal Medicaid redetermination requirements Inflation Reduction Act (IRA). ACS CAN actively monitors implementation of the Inflation Reduction Acts Medicare Drug Price negotiation provisions to ensure cancer patients have access to costly prescription drugs. ACS CAN also supports the Medicare Prescription Payment Plan, which allows Part D enrollees to spread their out-of-pocket costs over the plan year. Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2023 H.R.4189, S.2016. This bill expands coverage of telehealth services under Medicare. Nancy Gardner Sewell Multi-Cancer Early Detection Act, H.R. 2407. This bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, S.2085. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Lung Cancer Screening and Prevention Act, H.R.6693. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program Medical Nutrition Act H.R.6407, S.3297. A bill to amend title XVIII of the Social Security Act to expand the availability of medical nutrition therapy services under the Medicare program Equitable Community Access to Pharmacist Services Act H.R.1770, S.2477. This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, vaccines, and treatment for COVID-19, influenza, and certain other illnesses. Accelerating Kids Access to Care Act, S.2372, H.R.4758. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Medical Nutrition Therapy Act H.R.6407, S.3297. A bill to amend title XVIII of the Social Security Act to expand the availability of medical nutrition therapy services under the Medicare program

H.R. 4189 S. 2016 H.R. 2407 S. 2085 H.R. 6693 H.R. 6407 S. 3297 H.R. 1770 S. 2477 S. 2372 H.R. 4758

FY2024 Medical/Disease Research/Clinical Labs self-filed

Clinical Trial Modernization Act, H.R. 8412. Increase diversity in clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. NIH Clinical Trial Diversity Act, S.1701, H.R.3503. Legislation to increase the diversity of participants in all National Institutes of Health (NIH)-funded trials. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. LDT Regulation- A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory. Nancy Gardner Sewell Multi-Cancer Early Detection Act, H.R. 2407. This bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, S.2085. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Gabriella Miller Kids First Research Act 2.0, H.R. 623, S. 1523. This bill reauthorizes through FY2028 a pediatric disease research initiative within the National Institutes of Health (NIH) and requires the NIH to coordinate pediatric research activities to avoid duplicative efforts. Additionally, the Department of Health and Human Services must report to Congress about research funded through the initiative. Alan Reinstein Ban Asbestos Act, H.R.2402, S.1069. This bill generally prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. The President may, on application, grant exemptions from the prohibition in situations where it is necessary to protect national security interests.

H.R. 8412 S. 1701 H.R. 3503 H.R. 7090 H.R. 7418 H.R. 2407 S. 2085 H.R. 623 S. 1523 H.R. 2402 S. 1069

FY2024 Defense self-filed

Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP. DOD Congressionally Directed Medical Research Program.

FY2024 Budget/Appropriations as client

Health and Human Services appropriations for cancer research and prevention

FY2024 Budget/Appropriations as client

Health and Human Services appropriations for cancer research and prevention

FY2024 Budget/Appropriations as client

Health and Human Services appropriations for cancer research and prevention

FY2024 Health Issues as client

S.4260, Palliative Care and Hospice Education and Training Act

S. 4260

FY2024 Budget/Appropriations as client

Health and Human Services appropriations for cancer research and prevention

FY2024 Health Issues as client

S.4260, Palliative Care and Hospice Education and Training Act

S. 4260

FY2024 Health Issues self-filed

Access to Care Inflation Reduction Act (IRA). ACS CAN actively monitors implementation of the Inflation Reduction Acts Medicare Drug Price negotiation provisions to ensure cancer patients have access to costly prescription drugs. ACS CAN also supports the Medicare Prescription Payment Plan, which allows Part D enrollees to spread their out-of-pocket costs over the plan year. Enhanced Advanced Premium Tax Credits, H.R. 9774, Improving Health Insurance Affordability Act of 2023, S.5194. House and Senate bills would permanently extend the enhanced advanced premium tax credits. Retaining Access and Restoring Exclusivity (RARE) Act H.R.7383. This bill specifies that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drug exclusivity period) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. Help CoPays Act S.1375; Help Ensure Lower Patient Copays Act, H.R.830. This bill requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Safe Step Act, S.652, H.R. 2630. This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a group health plan or a health insurance issuer. Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2023 H.R.4189, S.2016. This bill expands coverage of telehealth services under Medicare. Telehealth Modernization Act of 2924, H.R. 7623. Modifies requirements relating to coverage of telehealth services under Medicare. Permanently expands telehealth flexibilities first authorized during the public health emergency. The Preserving Telehealth, Hospital, and Ambulance Access Act, H.R. 8261. This bill allows employers to offer stand-alone telehealth benefits to all employees. This includes employees who are eligible for enrollment in their employer's group health plan. Equitable Community Access to Pharmacist Services Act, H.R.1770, S.2477. This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, vaccines, and treatment for COVID-19, influenza, and certain other illnesses. This bill also requires drug manufacturers to report on the suppliers of ingredients used in their products. Drug Shortage Prevention Act, H.R. 3008. This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand for certain critical essential medicines that may result in a shortage. Protecting Americans from Unsafe Drugs Act of 2023, H.R. 2500. This bill expands the authority of the Secretary of the Department of Health and Human Services (HHS) to order the recall of controlled substances to cover all drugs. Ensuring Access to Lifesaving Drugs Act of 2023, H.R. 3793. This bill allows the Food and Drug Administration (FDA) to obtain additional information from manufacturers of life-saving drugs in order to assess and potentially modify the drug's expiration date. (The bill defines life-saving drug as a medical countermeasure or a drug that is in short supply and that is life-supporting, life-sustaining, or intended to be used to prevent or treat a debilitating disease or condition in humans or animals.) Specifically, the FDA may order a manufacturer of a life-saving drug to submit data and other information from any stage of the drug's development in order to assess the drug's stability and the longest supported expiration date. If such information is not readily available, the FDA may order the manufacturer to conduct additional studies. The FDA may require changes to the drug's label accordingly. Manufacturers that fail to comply are subject to civil penalties. Medical Device Shortage Reduction Act of 2023, H.R. 3807. This bill expands the scope of required notifications about medical device shortages beyond public health emergencies. Protecting PAHPA Action of 2023, H.R. 4697. ACS CAN is lobbying on all provisions related to drug shortages. This bill extends through FY2028 and modifies various programs and activities that support public health preparedness and response. The bill also addresses matters concerning shortages of drugs and medical devices and recalls of drugs. Essential Medicines Strategic Stockpile Act of 2023, H.R. 405. This bill requires the Department of Health and Human Services (HHS) to create a pilot program to test the effectiveness of acquiring, maintaining, managing, and distributing a stockpile of generic drugs at risk of shortage. Alan Reinstein Ban Asbestos Now Act of 2023, H.R. 2402, S. 1069. This bill prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. RAPID Reserve Act, S. 2510. This bill improves supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies. Rolling Active Pharmaceutical Ingredient and Drug Reserve Act, H.R.6802. A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies Senate Finance Committee Drug Shortage Proposal. This draft legislation would address the ongoing drug shortage crisis. Access to Breast Cancer Diagnosis Act of 2023, H.R.3851, S.2464. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Health Disparities Nancy Gardner Sewell Multi-Cancer Early Detection Act, H.R. 2407. This bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, S.2085. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer) Act, S.1840, H.R.3916. Reauthorization of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2024 through 2028 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, S.2821, H.R.1826. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.6693. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Health Equity and Accountability Act (HEAA), H.R. 9161, S. 4773. Legislation to eliminate racial and ethnic health disparities. We actively advocate for provisions (HEAA), which focuses on health inequalities, societal injustices, and their intersection with immigration status, age, disability, sex, gender, sexual orientation, and socioeconomic status. Increased Funding for the National Institute for Minority Health and Health Disparities. Reducing disparities in the use of recommended preventive services targeting three leading causes of death in the United States - cancer, heart disease, and diabetes. Cancer Drug Parity Act of 2023, S.2039, H.R.6301. Level the playing field for cancer patients by ensuring that the cost-sharing for oral anticancer drugs is on par with intravenous chemotherapy, thereby removing a significant financial obstacle to effective treatment. Henrietta Lacks Enhancing Cancer Research Act of 2019 Report. Request for Congress to urge the Government Accountability Office (GAO) to revisit the Henrietta Lacks Enhancing Cancer Research Act of 2019 report, with respect to promoting diverse participation in cancer clinical trials and addressing fully the request for insight into either implementation challenges for current federal activities or recommendations for additional activities and policy changes related to clinical trial diversity. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022 (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Gabriella Miller Kids First Research Act 2.0, H.R. 623, S. 1523. This bill reauthorizes through FY2028 a pediatric disease research initiative within the National Institutes of Health (NIH) and requires the NIH to coordinate pediatric research activities to avoid duplicative efforts. Additionally, the Department of Health and Human Services must report to Congress about research funded through the initiative. Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers (PREVENT) Act, H.R.3633. Legislation that would help prevent cancer and save lives by raising awareness about HPV and HPV-related cancers through a national campaign to educate providers, parents, and the public about the life-saving HPV vaccine. It would also boost resources for a federal initiative to provide access to timely cervical cancer screening and diagnostic services for uninsured and underserved individuals. Accelerating Kids Access to Care Act, S.2372, H.R.4758. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Creating Hope Reauthorization Act of 2024, H.R. 7384. This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.) Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA), S.2243. Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to ensure the U.S. Congress, for the first time, appropriates specific money for palliative care research, upon enactment of the FY2024 LHHS Appropriations bill. Patient Navigation for People with Cancer. Legislation and policies to increase access to patient navigation for people with cancer, prioritizing policies that create sustainable funding to ensure access to patient navigation services across the cancer continuum. Patient Navigation Assistance Act, H.R. 9446. This bill would require state Medicaid programs to provide patient navigation services for enrollees. Cancer Survivorship Comprehensive Cancer Survivorship Act (CCSA), S.2213, H.R.4363. ACS CAN supports legislation that sets new standards for survivorship from diagnosis to end of life, ensuring the best and most seamless experience for survivors, and their families and caregivers throughout the journey. CCSA will address gaps in survivorship care and develop needed standards to improve the overall patient-centered quality of care and navigation needs that cancer survivors and their families experience. Federal Health Care Programs Increased Funding Levels for Cancer Research and Prevention. Ensure continued progress in the fight against cancer at the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Advanced Research Projects Agency for Health (ARPA-H), and the Centers for Disease Control and Preventions (CDC) cancer programs. CDC Cancer Programs, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Regulatory issues related to healthy food and dietary guidelines PC CARE Act, H.R.1315. This bill establishes a committee to develop, implement, and periodically revise a plan to coordinate federal activities and programs concerning prostate cancer, including those related to research, screening, diagnosis, and treatment. Women and Lung Cancer Research and Preventive Services Act of 2023, H.R.4534, S.2245. This bill requires the Department of Health and Human Services to conduct an interagency review of the status of women and lung cancer. Department of Defense Appropriations Act, 2024 H.R.4365, S.2587. DOD Congressionally Directed Medical Research Program. Cancer Alan Reinstein Ban Asbestos Act, H.R.2402, S.1069. This bill generally prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. The President may, on application, grant exemptions from the prohibition in situations where it is necessary to protect national security interests. Nutrition Medical Nutrition Act H.R.6407, S.3297. A bill to amend title XVIII of the Social Security Act to expand the availability of medical nutrition therapy services under the Medicare program Farm, Food, and National Security Act of 2024, H.R.8467. To provide for the reform and continuation of agricultural and other programs of the Department of Agriculture through fiscal year 2029, and for other purposes. Rural Prosperity and Food Security Act. To provide for the reform and continuation of agricultural and other programs of the Department of Agriculture through fiscal year 2029, and for other purposes. Clinical Trials Clinical Trial Modernization Act, H.R. 8412. Increase diversity in clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. NIH Clinical Trial Diversity Act, S.1701, H.R.3503. Legislation to increase the diversity of participants in all National Institutes of Health (NIH)-funded trials. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

H.R. 9774 S. 5194 H.R. 7383 S. 1375 H.R. 830 S. 652 H.R. 2630 H.R. 4189 S. 2016 H.R. 7623 H.R. 8261 H.R. 1770 S. 2477 H.R. 3008 H.R. 2500 H.R. 3793 H.R. 3807 H.R. 4697 H.R. 405 H.R. 2402 S. 1069 S. 2510 H.R. 6802 H.R. 3851 S. 2464 H.R. 2407 S. 2085 S. 1840 H.R. 3916 S. 2821 H.R. 1826 H.R. 6693 H.R. 9161 S. 4773 S. 2039 H.R. 6301 H.R. 623 S. 1523 H.R. 3633 S. 2372 H.R. 4758 H.R. 7384 S. 2243 H.R. 9446 S. 2213 H.R. 4363 H.R. 1315 H.R. 4534 S. 2245 H.R. 4365 S. 2587 H.R. 6407 S. 3297 H.R. 8467 H.R. 8412 S. 1701 H.R. 3503 H.R. 7090 H.R. 7418

FY2024 Taxation/Internal Revenue Code self-filed

Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 8412. Increase diversity in clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Enhanced Advanced Premium Tax Credits H.R. 9774, Improving Health Insurance Affordability Act of 2023, S.5174. Bills to expand the eligibility of taxpayers for the refundable tax credit for coverage under a qualified health plan and increase cost-sharing subsidies under the Affordable Care Act

H.R. 8412 H.R. 7090 H.R. 7418 H.R. 9774 S. 5174

FY2024 Tobacco self-filed

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments; Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars; Increasing Access to Lung Cancer Screening Act, H.R. 4286. This bill provides for coverage without prior authorization requirements of annual lung cancer screenings under Medicaid, Medicare, and private health insurance for individuals for whom screenings are recommended under U.S. Preventive Services Task Force guidelines. It also expands Medicaid coverage of counseling and pharmacotherapy for cessation of tobacco use to all individuals, rather than only pregnant women.

H.R. 4286

FY2024 Budget/Appropriations self-filed

Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars; FY25 House Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. FY25 VA Appropriations for PACT Act Funding. ACS CAN advocates for full funding for the PACT Act. FY25 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY25 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of menthol, flavors, electronic cigarettes, and cigars.

FY2024 Medicare/Medicaid self-filed

Bridge To Medicaid Act: extends enhanced premium tax credits to low-income Medicaid enrollees in the coverage gap. Medicaid Unwinding. ACS CAN is working to ensure that states comply with federal law by actively monitoring their data submissions and tracking the impact on Medicaid beneficiaries. We will continue to urge the Centers for Medicare & Medicaid Services (CMS) to take corrective action if states fail to comply with federal Medicaid redetermination requirements Inflation Reduction Act (IRA). ACS CAN actively monitors implementation of the Inflation Reduction Acts Medicare Drug Price negotiation provisions to ensure cancer patients have access to costly prescription drugs. ACS CAN also supports the Medicare Prescription Payment Plan, which allows Part D enrollees to spread their out-of-pocket costs over the plan year. Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2023 H.R.4189, S.2016. This bill expands coverage of telehealth services under Medicare. Nancy Gardner Sewell Multi-Cancer Early Detection Act, H.R. 2407. This bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, S.2085. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Lung Cancer Screening and Prevention Act, H.R.6693. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program Medical Nutrition Act H.R.6407, S.3297. A bill to amend title XVIII of the Social Security Act to expand the availability of medical nutrition therapy services under the Medicare program Equitable Community Access to Pharmacist Services Act H.R.1770, S.2477. This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, vaccines, and treatment for COVID-19, influenza, and certain other illnesses. Accelerating Kids Access to Care Act, S.2372, H.R.4758. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Medical Nutrition Therapy Act H.R.6407, S.3297. A bill to amend title XVIII of the Social Security Act to expand the availability of medical nutrition therapy services under the Medicare program

H.R. 4189 S. 2016 H.R. 2407 S. 2085 H.R. 6693 H.R. 6407 S. 3297 H.R. 1770 S. 2477 S. 2372 H.R. 4758

FY2024 Medical/Disease Research/Clinical Labs self-filed

Clinical Trial Modernization Act, H.R. 8412. Increase diversity in clinical trials and make it easier for all persons with cancer to participate by reducing barriers to enrollment. Barriers may include ancillary (non-medical) costs, such as transportation and lodging, and remote access to trials, particularly for people who are underrepresented, including certain racial and ethnic groups, older adults, rural residents, and those with limited incomes. NIH Clinical Trial Diversity Act, S.1701, H.R.3503. Legislation to increase the diversity of participants in all National Institutes of Health (NIH)-funded trials. Harley Jacobsen Clinical Trial Participant Income Exemption Act, H.R.7090, H.R. 7418. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. LDT Regulation- A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory. Nancy Gardner Sewell Multi-Cancer Early Detection Act, H.R. 2407. This bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, S.2085. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Gabriella Miller Kids First Research Act 2.0, H.R. 623, S. 1523. This bill reauthorizes through FY2028 a pediatric disease research initiative within the National Institutes of Health (NIH) and requires the NIH to coordinate pediatric research activities to avoid duplicative efforts. Additionally, the Department of Health and Human Services must report to Congress about research funded through the initiative. Alan Reinstein Ban Asbestos Act, H.R.2402, S.1069. This bill generally prohibits the manufacture, process, use, and distribution in commerce of commercial asbestos or any mixture or article containing commercial asbestos. The President may, on application, grant exemptions from the prohibition in situations where it is necessary to protect national security interests.

H.R. 8412 S. 1701 H.R. 3503 H.R. 7090 H.R. 7418 H.R. 2407 S. 2085 H.R. 623 S. 1523 H.R. 2402 S. 1069